EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Surveillance for Chlamydia trachomatis variants escaping detection with the Aptima Combo 2 assay in Canada from 2019 to 2021

Felicia Roy iD, Jennifer Beirnes, Jason J LeBlanc iD, Suzanne Gibbons, Aida Sivro, Alberto Severini iD, Canadian Public Health Laboratory Network (CPHLN) Chlamydia Variant Working Group

Microbiology Spectrum · 2025

DOI: 10.1128/spectrum.02062-24 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Microbiology Spectrum, 2025. Verfasst von Felicia Roy und 6 weiteren Autor:innen. Beteiligte Einrichtung: National Microbiology Laboratory Branch, Public Health Agency of Canada, Winnipeg, Manitoba, Canada. Hauptthemen laut MEDLINE: Chlamydia trachomatis, Chlamydia Infections, Nucleic Acid Amplification Techniques, Molecular Diagnostic Techniques. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Nucleic acid amplification tests (NAATs) are the method of choice for Chlamydia trachomatis diagnosis, but these strategies are susceptible to target site mutations. C. trachomatis variants escaping detection with the Aptima Combo 2 (AC2) assay on the Hologic Panther instrument from 23S rRNA mutations have been reported in Nordic countries, England, Japan, and the United States. Given the potential for false negative results, this study investigated whether strains of C. trachomatis with AC2 target site mutations were present in Canada. Surveillance was conducted in Canadian laboratories from 2019 to 2021. Specimens suspected of AC2 target site mutations included those with low-value detections on the AC2 assay, with subsequent high-value detections on the Aptima Chlamydia Trachomatis (ACT) assay used for confirmatory testing. Specimens with AC2/ACT discrepant results were subjected to sequencing of the AC2 target (i.e., 23S rRNA). Sequencing revealed 15 (4.8%) diagnostic escape variants which were carrying either C1514T, G1523A, or G1526A mutations. All specimens with a diagnostic escape mutation were detected with a reformulated version of the AC2 assay. Overall, while the prevalence of C. trachomatis variants was rare, their presence in the Canadian population supports the use of the new AC2 kit formulation and the need for ongoing genetic surveillance for NAAT-based assays. IMPORTANCE Molecular tests are commonly used for the detection of sexually transmitted infections (STIs) like Chlamydia trachomatis . Mutations impacting C. trachomatis molecular target detection on the Hologic Panther AC2 assay have been reported in several countries, raising concerns about potential false negative results. This study showed C. trachomatis target detection failures in specimens submitted for C. trachomatis testing in Canadian laboratories from 2019 to 2021. A reformulated version of the AC2 molecular test is now available that can identify C. trachomatis strains harboring target site mutations that were impacted by the previous test formulation. While target site mutations were rare in Canada, revealing their presence is important to ensure accurate molecular detection of C. trachomatis with existing testing methods. This study supports ongoing genetic monitoring of C. trachomatis molecular test target sites, as well as the use of the reformulated test to avoid false negative results and subsequent transmissions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Chlamydia trachomatisChlamydia InfectionsNucleic Acid Amplification TechniquesMolecular Diagnostic TechniquesCanadaHumansRNA, Ribosomal, 23SMutationFemale

Stichwörter der Autor:innen

AptimaChlamydiaPantherdiagnosticmutationsequencingsurveillancevariant

Substanzen

RNA, Ribosomal, 23S

Autor:innen und Institutionen

  • National Microbiology Laboratory Branch, Public Health Agency of Canada, Winnipeg, Manitoba, Canada.
  • Division of Microbiology, Department of Pathology and Laboratory Medicine, Nova Scotia Health, Halifax, Nova Scotia, Canada.
  • Departments of Pathology, Medicine (Infectious Diseases), and Microbiology and Immunology, Dalhousie University, Halifax, Nova Scotia, Canada.
  • Department of Medical Microbiology and Infectious Diseases, Faculty of Health Sciences, University of Manitoba, Winnipeg, Manitoba, Canada.
  • Centre for the AIDS Programme of Research in South Africa (CAPRISA), Durban, South Africa.
  • Department of Medical Microbiology, University of KwaZulu-Natal, Durban, South Africa.

ORCID-Profile: Felicia Roy, Jason J LeBlanc, Alberto Severini

Zitieren

APA

Roy, F., Beirnes, J., LeBlanc, J. J., Gibbons, S., Sivro, A., Severini, A., & Canadian Public Health Laboratory Network (CPHLN) Chlamydia Variant Working Group (2025). Surveillance for Chlamydia trachomatis variants escaping detection with the Aptima Combo 2 assay in Canada from 2019 to 2021. Microbiology Spectrum. https://doi.org/10.1128/spectrum.02062-24

Vancouver

Roy F, Beirnes J, LeBlanc JJ, Gibbons S, Sivro A, Severini A, et al. Surveillance for Chlamydia trachomatis variants escaping detection with the Aptima Combo 2 assay in Canada from 2019 to 2021. Microbiology Spectrum. 2025. doi:10.1128/spectrum.02062-24

BibTeX
@article{Roy2025,
  author = {Roy, Felicia and Beirnes, Jennifer and LeBlanc, Jason J and Gibbons, Suzanne and Sivro, Aida and Severini, Alberto and Canadian Public Health Laboratory Network (CPHLN) Chlamydia Variant Working Group, Canadian Public Health Laboratory Network (CPHLN) Chlamydia Variant Working Group},
  title = {Surveillance for Chlamydia trachomatis variants escaping detection with the Aptima Combo 2 assay in Canada from 2019 to 2021},
  journal = {Microbiology Spectrum},
  year = {2025},
  doi = {10.1128/spectrum.02062-24}
}
Kostenlos starten →